Separately, HC Wainwright assumed coverage on Bio-Path in a research report on Tuesday, July 16th. They set a “buy” rating and a $28.00 target price on the stock.
Shares of NASDAQ BPTH traded up $0.15 during midday trading on Thursday, reaching $13.11. 82,397 shares of the company’s stock were exchanged, compared to its average volume of 214,280. Bio-Path has a 52-week low of $1.61 and a 52-week high of $73.52. The company has a market capitalization of $37.10 million, a PE ratio of -0.91 and a beta of 3.16. The stock’s fifty day moving average price is $13.67.
A hedge fund recently bought a new stake in Bio-Path stock. Gainplan LLC purchased a new position in Bio-Path Holdings Inc (NASDAQ:BPTH) in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 10,000 shares of the company’s stock, valued at approximately $204,000. Bio-Path makes up about 0.2% of Gainplan LLC’s investment portfolio, making the stock its 21st largest holding. Gainplan LLC owned 0.40% of Bio-Path at the end of the most recent reporting period. Institutional investors own 10.77% of the company’s stock.
Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.
See Also: What are gap-up stocks?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.